Read as much as you want on, anywhere and anytime, for just 99¢.

Mass. Movers

Merck acquires Idenix, hepatitis C drug maker

Merck agreed to pay $3.85 billion for Idenix.

Associated Press

Merck agreed to pay $3.85 billion for Idenix.

Continue reading below

Shares of Cambridge-based Idenix Pharmaceuticals Inc. soared this week after Merck & Co. agreed to pay $3.85 billion for the biotech that is developing drugs to cure hepatitis C, a staggering price for a small company with fewer than 100 employees. The market for hepatitis C treatments, estimated at $200 billion worldwide over the next decade and an half, is dominated by Sovaldi, a fast-selling pill made by California’s Gilead Sciences Inc.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of